Double-Punch CAR-T therapy tested in kids with tough leukemia
NCT ID NCT06408194
Summary
This early-phase study is testing the safety of giving two different types of genetically modified immune cell therapies, one after the other, to children and young adults whose B-cell leukemia has come back or hasn't responded to treatment. The goal is to see if a second, experimental CAR-T cell infusion given about a month after a standard, approved one is safe and feasible. Researchers will find the safest dose and check for early signs that this approach might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.